Already described biomarkers (see Section 3.1.2) such as NGAL, IL18, L-FABP, and KIM-1 seem to have a great potential for differentiating between HRS-AKI and ATN-AKI [122,123,131]. This evidence concerns the gene IL18 and acute kidney injury.